Latest News
Glaukos Corporation
- Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery
- Glaukos Says Phase 4 Trial of iDose TR Meets Primary Efficacy Endpoint
- Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics for Biologic to Treat Retinal Diseases
- Glaukos says late-stage eye disease treatment shows lasting benefits after single dose
- Glaukos' Epioxa maintains corneal flattening and visual gains through 3 years in keratoconus
- Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
- Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
- Stifel reiterates Glaukos stock rating on strong Epioxa survey By Investing.com
- Form 144 GLAUKOS Corp For: 26 September
- Glaukos Launches Campaign With NBA Champ Stephen Curry to Raise Awareness of Keratoconus
- Glaukos courts NBA champion Stephen Curry for new keratoconus awareness campaign
- Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Headlines from the last 30 days, linking to the original publishers. See all market news →